Enanta Pharmaceuticals Reports Mixed Q2 2026 Results, Advances Key Clinical Trials
Event summary
- Enanta reported $17.2M in Q2 2026 revenue, up from $14.9M in Q2 2025, driven by increased AbbVie royalty revenue.
- Net loss narrowed to $13.1M (Q2 2026) from $22.6M (Q2 2025), with R&D expenses decreasing to $19.4M from $28.1M.
- Phase 1 trial of EDP-978, an oral KIT inhibitor for chronic urticaria, initiated in Q2 2026.
- Company expects to file an IND for EPS-3903, an oral STAT6 inhibitor, and nominate an MRGPRX2 development candidate in the second half of 2026.
- Oral arguments in Enanta’s lawsuit against Pfizer over PAXLOVID patent infringement held in May 2026, with a decision expected by September 2026.
The big picture
Enanta’s Q2 2026 results reflect a strategic focus on advancing its immunology and virology pipelines while managing royalty revenue from AbbVie’s HCV treatments. The company’s financial stability is bolstered by a strong cash position and ongoing royalty income, but its success hinges on the clinical and regulatory progress of its key programs. The outcome of the Pfizer litigation could significantly impact Enanta’s financial trajectory.
What we're watching
- Royalty Revenue Dynamics
- How sustained growth in AbbVie’s product sales will impact Enanta’s royalty revenue and financial stability.
- Clinical Trial Execution
- The pace at which Enanta advances its immunology and virology programs, particularly EDP-978 and zelicapavir.
- Litigation Outcomes
- Whether Enanta’s lawsuit against Pfizer will result in favorable damages, affecting its financial position.
Related topics